Technology & Innovation

SHERIDAN, WYOMING - December 15, 2025 - TuHURA Biosciences (NASDAQ: HURA) has provided a corporate update following a recent $15.6 million equity financing, detailing near-term milestones across its Phase 3 IFx-2.0 program in Merkel cell carcinoma, its VISTA-inhibiting antibody TBS-2025 in AML, and its Delta Opioid Receptor (DOR)-focused conjugate platform aimed at overcoming resistance to cancer immunotherapy.

SHERIDAN, WYOMING - December 15, 2025 - TuHURA Biosciences, Inc. (NASDAQ:HURA) announced that Kintara's REM-001 clinical trial in ten metastatic cutaneous breast cancer patients met its primary endpoint demonstrating safety, a contractual milestone that is expected to trigger distribution of TuHURA common stock to eligible contingent value right (CVR) holders.

SHERIDAN, WYOMING - December 15, 2025 - ARIDGE has introduced new details on its next-generation A868 flying car concept and confirmed fresh progress at its flying car manufacturing plant, as the company positions two flight systems to serve different segments of China's emerging low-altitude mobility market.

Two flight systems target distinct low-altitude travel needs
ARIDGE framed the low-altitude economy as the next major growth frontier following new energy vehicles, and outlined a dual-product strategy built around different operating missions. The company is developing:

SHERIDAN, WYOMING - December 15, 2025 - XPENG AEROHT has secured a manned aircraft special flight permit from the UAE's General Civil Aviation Authority (GCAA) for its modular flying car "Land Aircraft Carrier" in Ras Al Khaimah, enabling manned flight tests across the country and marking a notable step in the overseas commercialization of China's low-altitude eVTOL technology.

Aviation permission becomes a market-entry signal for advanced air mobility
The permit, granted in Ras Al Khaimah, is positioned as the first such authorization obtained by a Chinese flying car company overseas. For B2B stakeholders-from mobility operators to public-sector agencies-regulatory access is often the gating factor that turns "future mobility" narratives into measurable pilots, procurement conversations, and infrastructure planning.

SHERIDAN, WYOMING - December 15, 2025 - XPENG AEROHT, the flying car affiliate of Chinese EV maker XPENG, has begun trial production at what it describes as the world's first intelligent factory for mass-produced flying cars-an operational milestone as next-generation mobility moves from prototypes to industrial output.

Trial production signals a commercialization inflection point
The company started trial production on November 3, 2025, positioning the facility as a bridge between engineering validation and repeatable manufacturing. For the broader eVTOL and "low-altitude mobility" ecosystem, factory readiness matters because it shifts the discussion from flight demonstrations to supply chains, quality systems, and scalable assembly-areas that typically determine whether new vehicle categories can reach customers on schedule.

SHERIDAN, WYOMING - December 15, 2025 - Shanghai is sharpening its push to become a leading center for merger-and-acquisition activity, as the 2025 Mergers and Acquisitions Finance Conference spotlighted stronger regional deal momentum and unveiled a new market index intended to track China's evolving M&A environment.

Policy momentum behind listed-company restructuring
The conference took place as Shanghai marks one year since releasing a three-year action plan aimed at supporting M&A among listed firms. In practical terms, the message to corporate leaders and capital providers is clear: policy alignment and financial-market infrastructure are being positioned to support more transactions that improve efficiency, accelerate industrial upgrading, and strengthen competitiveness in key sectors.

SHERIDAN, WYOMING - December 11, 2025 - Saol Therapeutics is turning an FDA rejection into a potential regulatory test case, as the biotech prepares to argue that its pyruvate dehydrogenase complex deficiency (PDCD) drug SL1009 is the ideal "poster child" for the agency's new Rare Disease Evidence Principles (RDEP) framework at a Type A meeting on December 18.

Saol Recasts a Complete Response Letter as a Strategic Opening

On September 8, Saol disclosed that the FDA had issued a complete response letter (CRL) for SL1009, an oral formulation of sodium dichloroacetate for children with PDCD, a genetic disorder affecting fewer than 1,000 people in the U.S. The CRL, according to CEO Dave Penake, "suggested that we would need to do an additional adequate and well controlled clinical trial," and that "and that's not feasible to be done by our company and in this patient population."

SHERIDAN, WYOMING - December 11, 2025 - Terns Pharmaceuticals is rapidly emerging as a serious contender in chronic myeloid leukemia (CML), after early clinical data for its allosteric BCR/ABL1 inhibitor TERN-701 more than doubled response rates seen with Novartis' approved STAMP inhibitor Scemblix in comparable settings and sent the biotech's share price sharply higher.

Best-in-Disease Early Efficacy Raises the Bar in CML

At the American Society of Hematology (ASH) annual meeting, Terns reported Phase I data from the CARDINAL trial in previously treated CML patients, with 38 participants evaluable for efficacy. TERN-701 achieved a major molecular response (MMR) rate of 75% at week 24, with 64% of patients reaching MMR overall in the dataset presented. The investigational agent also supported simple once-daily dosing without a food effect, improving convenience relative to many existing tyrosine kinase inhibitor (TKI) regimens.

SHERIDAN, WYOMING - December 11, 2025 - Mercedes-Benz is expanding its sustainability playbook with "Tomorrow XX", a cross-portfolio technology program designed to decarbonize vehicle components, scale circular materials and turn end-of-life cars into a strategic raw-materials source. For OEMs, suppliers and material innovators, the initiative signals how one of the world's leading premium automotive brands plans to industrialize low-carbon, circular design across its global lineup.

Holistic sustainability roadmap across the Mercedes-Benz portfolio

Tomorrow XX extends the holistic, multi-disciplinary approach first showcased in the VISION EQXX and CONCEPT AMG GT XX to the entire product portfolio, across all drivetrains. From the earliest design stages through to end-of-life, every component and material is being scrutinized for CO₂ impact, resource intensity and recyclability.

SHERIDAN, WYOMING - December 10, 2025 - Pfizer Inc. is expanding its cardiometabolic ambitions through an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical, to develop, manufacture and commercialize YP05002, an oral GLP-1 receptor agonist currently in Phase 1 for chronic weight management. The deal strengthens Pfizer's position in the fast-moving obesity field and adds a differentiated small-molecule asset to its portfolio of metabolic disease candidates.

Strategic Bet on Small-Molecule GLP-1 in Obesity

Under the agreement, China-based YaoPharma will complete an ongoing Phase 1 study of YP05002 before transferring global development and commercialization rights to Pfizer. For Pfizer, the asset fits neatly into a strategy that aims to pair novel mechanisms with scalable, oral delivery formats for obesity and adjacent cardiometabolic conditions.